What is the difference between CJC-1295 (without DAC) and GHRP-2?

CJC-1295 (without DAC): CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. GHRP-2: Synthetic hexapeptide that stimulates pulsatile growth hormone release from the anterior pituitary by acting on the ghrelin receptor (GHSR-1a).

How is CJC-1295 (without DAC) administered in research settings?

In research settings, CJC-1295 (without DAC) is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is GHRP-2 administered in research settings?

In research settings, GHRP-2 is typically administered via the subcutaneous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›CJC-1295 (without DAC) vs GHRP-2

Peptide Comparison

CJC-1295 (without DAC) vs GHRP-2

Name: CJC-1295 (without DAC) vs GHRP-2 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

CJC-1295 (without DAC)

CJC 1295

Fat LossResearch Only

Half-life: ~30 minutes

491 providers listed

Full CJC-1295 (without DAC) profile →

GHRP-2

Growth Hormone Releasing Peptide 2

PerformanceUnder clinical reviewResearch Only

Half-life: 15–60 minutes

47 providers listed

Full GHRP-2 profile →

Bottom line

CJC-1295 (without DAC) carries stronger published evidence (RCT, 3 key studies) than GHRP-2 (Cohort study, 2); both are research compounds.

Quick Verdict

CJC-1295 (without DAC)

Half-life

~30 minutes

GHRP-2

Half-life

15–60 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	CJC-1295 (without DAC)
Lower typical price per mg	GHRP-2
More provider options (491 vs 47)	CJC-1295 (without DAC)

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

CJC-1295 (without DAC)

GHRP-2

Mechanism Family

GH / IGF Axis

Half-life

~30 minutes

15–60 minutes

FDA Status

nomination withdrawn

Under clinical review

Admin Routes

subcutaneous

subcutaneous, intramuscular

Availability

Research Only

Providers

491 listed

47 listed

FDA Update

—

Under clinical review

Avail. Notes

GHRH analog — the truncated 1-29 form (Mod GRF 1-29), WITHOUT the Drug Affinity Complex (DAC). No FDA approval; not on the FDA 503A bulks list. WADA prohibited (S2) as a growth-hormone-releasing factor. Sold as a research chemical only.

Approved for diagnostic GH stimulation testing in Japan (Kaken Pharma) but NOT FDA-approved. Listed on the FDA Category 2 'significant safety risks' bulk-substances list (503B designation, added September 2023). WADA prohibited. Research chemical in US.

Research Evidence

CJC-1295 (without DAC)

RCT · 3 key studies · most recent 2026

GHRP-2

Cohort study · 2 key studies · most recent 2020

Research Citations

CJC-1295 (without DAC)

RCT1997 · Journal of Clinical Endocrinology and Metabolism

Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)…

RCT1997 · Journal of Clinical Endocrinology and Metabolism

Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune syst…

Review2026 · JBJS Rev

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…

GHRP-2

Cohort2020 · Endocrine Journal

Preoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hyp…

Review2014 · Neurologia Medico-Chirurgica

Adult growth hormone deficiency: current concepts

About CJC-1295 (without DAC)

CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.

Research Areas

GH and IGF-1 elevationsustained GHRH receptor agonismbody composition supportrecovery enhancementGH axis restoration

About GHRP-2

Synthetic hexapeptide that stimulates pulsatile growth hormone release from the anterior pituitary by acting on the ghrelin receptor (GHSR-1a). Commonly stacked with GHRH analogs such as CJC-1295 or Sermorelin to amplify GH output synergistically.

Research Areas

potent GH release via GHS-R1a agonismco-stimulation of cortisol and prolactin (non-selective profile)synergistic GH amplification when combined with GHRH analogsvalidated diagnostic GH stimulation agent (Japan clinical use)

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

CJC-1295 (without DAC)

Warnings & Cautions

Active malignancy — caution (GH/IGF-1 is mitogenic)Pregnancy — cautionKnown hypersensitivityGlucose intolerance / insulin resistance

Class-based (investigational)

Suggested Monitoring

IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

GHRP-2

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

IGF-1Fasting glucoseHbA1cCortisolInsulin

GHRP-2 stimulates GH and cortisol release. Research protocols measure IGF-1 for GH axis response and baseline cortisol given the compound's adrenal stimulation. Glucose markers are standard given GH's effect on insulin sensitivity.

Used Together?

CJC-1295 (without DAC)

Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.

GHRP-2

Corticosteroids
Research notes that GHRP-2 stimulates cortisol and ACTH release via the HPA axis. Combined use with corticosteroid medications may affect glucocorticoid regulation. Consult your prescriber before combining.

Price (per mg)

CJC-1295 (without DAC)

$7.99/mg

$6.80 – $11.39 range

62 vendors

View price index →Find providers →

GHRP-2

$3.90/mg

$2.76 – $5.00 range

25 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

CJC-1295 (without DAC)

491 listed

Browse directory →

Providers offering

GHRP-2

47 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated September 28, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). CJC-1295 (without DAC) vs GHRP-2 — Per-mg Price Comparison. Retrieved October 15, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/ghrp-2

https://peptidebase.io/peptides/compare/cjc-1295/ghrp-2 Methodology License Download JSON Download CSV